DEUTERIUM-ENRICHED DECITABINE
    21.
    发明申请
    DEUTERIUM-ENRICHED DECITABINE 审中-公开
    富含DEUTERIUM-ENRICHED DECITABINE

    公开(公告)号:US20090075920A1

    公开(公告)日:2009-03-19

    申请号:US12196853

    申请日:2008-08-22

    CPC分类号: C07H19/12

    摘要: The present application describes deuterium-enriched decitabine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.

    摘要翻译: 本申请描述了富含氘的地西他滨,其药学上可接受的盐形式,以及使用其的治疗方法。

    SYNTHESIS OF 5-AZACYTIDINE
    24.
    发明申请
    SYNTHESIS OF 5-AZACYTIDINE 有权
    5-AZACYTIDINE的合成

    公开(公告)号:US20090005551A1

    公开(公告)日:2009-01-01

    申请号:US12208238

    申请日:2008-09-10

    IPC分类号: C07H19/12

    CPC分类号: C07H19/12

    摘要: The present invention provides a method for the preparation of 5-azacytidine, wherein 5-azacytidine is represented by the structure: The method involves the silylation of 5-azacytosine, followed by the coupling of silylated 5-azacytosine to a protected β-D-ribofuranose derivative. The coupling reaction is catalyzed by trimethylsilyl trifluoromethanesulfonate (TMS-Triflate).

    摘要翻译: 本发明提供了制备5-氮杂胞苷的方法,其中5-氮杂胞苷由以下结构表示:该方法包括5-氮杂胞嘧啶的甲硅烷基化,然后将甲硅烷基化的5-氮杂胞嘧啶与保护的β- 呋喃核糖衍生物。 偶联反应由三氟甲磺酸三甲基甲硅烷基酯(TMS-Triflate)催化。

    Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
    26.
    发明授权
    Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof 有权
    嘌呤衍生物作为腺苷A1受体激动剂及其使用方法

    公开(公告)号:US07423144B2

    公开(公告)日:2008-09-09

    申请号:US11137632

    申请日:2005-05-25

    摘要: The invention relates to Purine Derivatives; compositions comprising an effective amount of a Purine Derivative; and methods for reducing an animal's rate of metabolism, protecting an animal's heart against myocardial damage during cardioplegia; or for treating or preventing a cardiovascular disease, a neurological disorder, an ischemic condition, a reperfusion injury, obesity, a wasting disease, or diabetes, comprising administering an effective amount of a Purine Derivative to an animal in need thereof.

    摘要翻译: 本发明涉及嘌呤衍生物; 包含有效量的嘌呤衍生物的组合物; 以及降低动物代谢率的方法,保护动物的心脏免受心脏停搏期间的心肌损伤; 或用于治疗或预防心血管疾病,神经障碍,缺血状况,再灌注损伤,肥胖症,消耗性疾病或糖尿病,包括向有需要的动物施用有效量的嘌呤衍生物。